• The efficacy of hemostasis in gynecological practice
en To content

The efficacy of hemostasis in gynecological practice

HEALTH OF WOMAN. 2016.10(116):94–97; doi 10.15574/HW.2016.116.94 

The efficacy of hemostasis in gynecological practice

Grishenko O. V., Bobrytska V. V.

Kharkiv medical Academy of postgraduate education

The objective: to study the clinical efficacy of Cyclokapron-Zdorovje and its impact on the parts of the system in cases of abnormal uterine bleeding (AUB), as well as a comparison of the effectiveness of the complex method of stop bleeding and hormonal hemostasis.

Patients and methods. The study included 60 patients with AUB at the age 35-46 years with metrology. The patients were divided into three groups according to the therapy: group I (n=20) received the drug Cyclokapron-Zdorovje 10 ml (1 g tranexamic acid) for the purpose of hemostasis; group II (n=20) surgical hemostasis – separate curettage or hysteroscopy combined with intravenous Cyclokapron 10 ml (1 g); group III (n=20), in which hemostasis was achieved using a combined estrogen-progestin preparation (ethinyl estradiol 30 mg in combination with desogestrel 150 mg).

Results. Treatment of abnormal uterine bleeding using intravenous infusions of Cyclokapron 1000mg was performed. The medicine was administered to patients before the curettage, as well as the hemostatic agent in patients with advanced endometrial histological result of the state. Intravenous dosage of 1000mg Cyclokapron in women with abnormal uterine bleeding achieves significant hemostatic effect, reduces total blood loss.

Conclusion. The medicine is clinically effective and safe. The drug can be recommended for inclusion in the standard algorithm for emergency patients with AUB. In addition, the safety of the drug can be recommended for the whole spectrum of possible clinical situations in obstetrics and gynecology, complicated by hemorrhage.

Key words: abnormal uterine bleeding, hemostasis, Cyclokapron-Zdorovje.


1. Anomalnyie matochnyie krovotecheniya (Adaptirovannoe klinicheskoe rukovodstvo)// Prikaz MZ Ukrainyi 353 «Ob utverzhdenii i vnedrenii mediko-tehnologicheskih dokumentov po standartizatsii meditsinskoy pomoschi pri anomalnyih matochnyih krovotecheniyah» ot 13.04.2016 g.

2. Karpenko N. 2014. Traneksamovaya kislota v lechenii anomalnyih matochnyih krovotecheniy. Zdorov’ya Ukraуini 3:49.

3. Shevchenko YuL, Stoyko YuM, Zamyatin MN. 2008. Krovosberegayuschiy effekt traneksamovoy kislotyi: klinicheskoe znachenie. Farmateka 16:17–22.

4. Gultekin M, Diribas K, Buru E, Gцkзeoglu MA. 2009. Role of a non-hormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding. Clin Exp Obstet Gynecol. 36(3):163. PMid:19860359

5. Senthong AJ, Taneepanichskul SJ. 2009, Apr. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. Med Assoc Thai. 92(4):461–5.